Document is current
Any future updates will be listed below
-
Authors
Klein-Goldberg, Anat
Voloshin, Tali https://orcid.org/0000-0002-5463-3941
Zemer Tov, Efrat
Paz, Rom
Somri-Gannam, Lina
Volodin, Alexandra
Koren, Lilach
Lifshitz, Lena
Meir, Aviv
Shabtay-Orbach, Ayelet
Blatt, Roni
Cahal, Shay
Tempel-Brami, Catherine
Wainer-Katsir, Kerem https://orcid.org/0009-0004-5634-8978
Kan, Tal
Koltun, Bella
Brant, Boris
Barsheshet, Yiftah
Haber, Adi
Giladi, Moshe https://orcid.org/0000-0003-1489-4175
Weinberg, Uri
Palti, Yoram
-
Funding
Funding for this research was provided by:
Novocure Ltd
- License Information
-
More Information
Article History
Received: 14 August 2024
Revised: 18 February 2025
Accepted: 17 March 2025
First Online: 27 March 2025
Competing interests
: AKG, TV, EZ, RP, LSG, AV, LK, LL, AM, AO, RB, SC, CTB, KWK, TK, BK, BB, YB, AH, MG, and UW are employees of Novocure, hold company stocks, and TTFields-related patents. YP is the founder of Novocure, holds company stocks, and TTFields-related patents.
: All animal studies were approved by the Animal Experimentation Committee according to the Ministry of Health by the Israel National Council for Animal Experimentation (approval numbers: NPC-No-IL-2110-101-4 for ovarian model; NPC-No-IL-2303-245-4 for lung model) and performed in accordance with guidelines and regulations.
